Metabolomic Profiling of Biomarkers for Early Detection of Type 2 Diabetes Mellitus

[1]Faiza Maqsood, [2]Umar Tipu, [3]Mansoor Musa, [4]Qamar Abbas, [5]Dr. Muhammad Zubair, [6]Dr Qamar Yasmeen (PhD)

Submission: 01 December 2025 | Acceptance: 05 January 2026 | Publication: 16 February 2026

[1]UHS Lahore
[2]PIMS Islamabad
[3]UHS Lahore
[4]PIMS Islamabad
[5]Associate Professor of Pathology Saidu Medical College, Swat/ Saidu group of Teaching Hospitals,Swat.
[6]Assistant professor Biochemistry, Niazi medical and dental college Sargodha

ABSTRACT:

Background: Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and hyperglycemia. Early detection of T2DM is critical for effective management and prevention of complications. Recent advancements in metabolomics have enabled the identification of potential biomarkers for the early detection of T2DM, providing new insights into its pathophysiology.

Aim: The aim of this study was to identify metabolomic biomarkers associated with the early detection of Type 2 Diabetes Mellitus using high-throughput analytical techniques.

Methods: This study was conducted at Services Hospital, Lahore, from May 2024 to April 2025. A total of 90 participants were enrolled, consisting of 45 individuals with prediabetes and 45 age- and gender-matched healthy controls. Blood samples were collected and analyzed using liquid chromatography-mass spectrometry (LC-MS) to identify and quantify metabolites. Statistical analysis was performed to determine significant differences in metabolite profiles between the groups.

Results: Several metabolites were identified as significantly altered in the prediabetic group compared to healthy controls. Key metabolites involved in glucose metabolism, fatty acid oxidation, and inflammation were found to be dysregulated. Multivariate analysis revealed a panel of biomarkers that could distinguish between prediabetic and healthy individuals with high sensitivity and specificity.

Conclusion: Metabolomic profiling of blood samples has proven to be a promising tool for the early detection of Type 2 Diabetes Mellitus. The identified biomarkers could potentially serve as diagnostic indicators for individuals at risk, enabling earlier intervention and better management of the disease.

Keywords: Type 2 Diabetes Mellitus, Metabolomic Profiling, Biomarkers, Early Detection, Liquid Chromatography-Mass Spectrometry, Prediabetes, Glucose Metabolism.

INTRODUCTION:

Type 2 diabetes mellitus (T2DM) has become a major global health challenge due to its increasing prevalence and the significant burden it places on healthcare systems. T2DM is a chronic metabolic disorder characterized by insulin resistance and impaired glucose metabolism, which leads to elevated blood glucose levels. The onset of T2DM is often insidious, and by the time clinical symptoms appear, patients may have already experienced substantial damage to organs, including the heart, kidneys, and eyes [1]. Early detection of T2DM is crucial for preventing or delaying its complications, making it an important area of research.

Traditionally, the diagnosis of T2DM has relied on blood glucose measurements, such as fasting plasma glucose (FPG) and oral glucose tolerance tests (OGTT). While these methods are effective, they have limitations, including the need for fasting and the lack of sensitivity during the early stages of the disease. Furthermore, these tests do not fully capture the complex biochemical processes that occur in the body prior to the clinical onset of diabetes [2]. Therefore, there has been growing interest in exploring novel

biomarkers that could offer earlier and more accurate detection of T2DM, particularly through metabolomic profiling.

Metabolomics, a rapidly advancing field of study, focuses on the comprehensive analysis of small-molecule metabolites in biological samples. This approach offers a unique opportunity to examine metabolic changes that occur in response to various physiological conditions, including disease states like T2DM [3]. Metabolomic profiling involves the identification and quantification of metabolites in blood, urine, or other biological fluids, providing a snapshot of an individual's metabolic state. By comparing the metabolomic profiles of individuals with T2DM to those without, researchers have identified several potential biomarkers that may be indicative of early-stage diabetes, even before the onset of noticeable symptoms [4].

In recent years, a variety of studies have applied metabolomic profiling techniques to identify biomarkers associated with T2DM. These studies have focused on various metabolic pathways, including lipid metabolism, amino acid metabolism, and the regulation of insulin and glucose homeostasis. By examining changes in these pathways, researchers have been able to identify specific metabolites, such as altered levels of branched-chain amino acids (BCAAs), short-chain fatty acids, and acylcarnitines, that are associated with insulin resistance and the early stages of T2DM [5]. These metabolites have been proposed as potential candidates for early detection and risk stratification of T2DM, offering insights into the disease's pathophysiology.

Metabolomic profiling has also been used to investigate the effects of lifestyle factors, such as diet and exercise, on metabolic health [6]. Several studies have demonstrated that certain dietary patterns, physical activity, and weight loss can influence the metabolic profile, potentially reversing or delaying the progression of T2DM. As a result, metabolomics holds promise not only for identifying biomarkers of early disease but also for monitoring the effectiveness of therapeutic interventions aimed at preventing or managing T2DM [7].

Metabolomic profiling has emerged as a powerful tool for the early detection of T2DM. The identification of specific biomarkers associated with the disease could lead to the development of more sensitive and accurate diagnostic tests, facilitating earlier intervention and improving patient outcomes. As research in this field continues to evolve, it is anticipated that metabolomic profiling will play an increasingly important role in the fight against T2DM, ultimately contributing to better disease management and prevention strategies [8].

MATERIALS AND METHODS:

Study Place:

The study was conducted at Services Hospital, Lahore, a leading healthcare facility with a diverse patient population and well-equipped diagnostic labs, providing an ideal setting for the study of biomarkers related to Type 2 Diabetes Mellitus (T2DM).

Study Duration:

The study took place from May 2024 to April 2025, spanning a period of one year to allow for the collection of sufficient data, the identification of biomarkers, and the analysis of metabolomic profiles associated with the early stages of T2DM.

Study Population:

The study included a total of 90 participants who were selected based on predefined inclusion and exclusion criteria. Participants were categorized into two groups: 45 individuals diagnosed with pre-diabetes or early-stage Type 2 Diabetes Mellitus, and 45 healthy control subjects who had no history of diabetes. The inclusion criteria for the T2DM group included individuals aged 30-60 years, diagnosed with pre-diabetes or early-stage diabetes based on their fasting blood glucose levels (FPG) and HbA1c levels. The control group comprised individuals matched for age, gender, and socio-economic status, with normal blood glucose and HbA1c levels.

Sampling and Data Collection:

The study employed a cross-sectional design, where participants were recruited through hospital outpatient clinics. Informed consent was obtained from all participants, ensuring they understood the purpose and procedures of the study. A detailed medical history was recorded for each participant, and demographic data including age, gender, BMI, and lifestyle factors were documented.

Metabolomic profiling was performed using serum samples collected from each participant after overnight fasting. Blood samples were processed in the laboratory to extract metabolites for analysis. The metabolomic analysis was carried out using high-resolution mass spectrometry (HRMS), which allowed for the detection of a wide array of metabolites with high sensitivity and specificity. Metabolites of interest, including amino acids, lipids, and sugars, were quantified, and their levels were compared between the T2DM group and the healthy controls.

Data Analysis:

Data analysis was performed using statistical software (e.g., SPSS or R). Descriptive statistics were used to summarize demographic data and baseline characteristics. The metabolic profiles of both groups were compared using univariate and multivariate statistical techniques. The significance of differences between the two groups was assessed using t-tests for continuous variables and chi-square tests for categorical variables. A p-value of less than 0.05 was considered statistically significant. Additionally, machine learning algorithms such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) were applied to identify potential biomarkers that could differentiate between the T2DM and control groups.

Ethical Considerations:

The study was conducted in accordance with the ethical guidelines established by the hospital's institutional review board (IRB). Confidentiality of participant data was maintained throughout the study, and all participants were assured that their involvement in the study was voluntary, with the option to withdraw at any time without any consequences.

Outcome Measures:

The primary outcome of the study was to identify a panel of metabolomic biomarkers that could serve as early indicators of Type 2 Diabetes Mellitus. Secondary outcomes included the analysis of specific metabolic pathways that may be disrupted in the early stages of T2DM and the relationship between metabolomic profiles and clinical parameters such as fasting glucose levels, HbA1c, and insulin sensitivity.

Limitations:

The study was limited by the relatively small sample size and the cross-sectional design, which prevents the establishment of causal relationships. Additionally, due to the nature of the metabolomic profiling, the results are dependent on the specific technology and analytical methods used. Further longitudinal studies with larger sample sizes are needed to validate the findings and explore the long-term potential of identified biomarkers in the early detection and management of Type 2 Diabetes Mellitus.

RESULTS:

The study aimed to explore the metabolomic profiling of biomarkers for the early detection of Type 2 Diabetes Mellitus (T2DM) in a cohort of 90 participants at Services Hospital, Lahore, from May 2024 to April 2025. Various metabolic markers were analyzed to assess their potential for early detection of T2DM.

Table 1: Distribution of Participants by Metabolic Biomarkers:

Metabolic Biomarker	Mean Value ± SD (mg/dL)	Normal Range	Abnormal Range

Fasting Glucose	104.2 ± 16.5	70–100	>100
Insulin Levels	16.4 ± 4.7	6–20	>20
HbA1c	5.8 ± 0.7	4.5–5.6	>5.6
Triglycerides	170.3 ± 45.2	50–150	>150
Leptin	22.1 ± 6.3	4–16	>16

The fasting glucose levels in the study population averaged 104.2 ± 16.5 mg/dL, indicating that a substantial number of participants had elevated glucose levels, which is a critical marker for the potential onset of T2DM. Insulin levels were measured at an average of 16.4 ± 4.7 mg/dL, with many participants exceeding the normal range (>20 mg/dL), signifying a state of insulin resistance, which is often seen in prediabetes and early T2DM. HbA1c values showed an average of 5.8 ± 0.7%, where most participants presented with values higher than the normal range, further supporting the suspicion of early T2DM. Triglyceride levels were elevated in the cohort, with a mean of 170.3 ± 45.2 mg/dL, surpassing the normal threshold of 150 mg/dL, indicating dyslipidemia, which is commonly associated with Type 2 diabetes. Leptin levels also exceeded the normal range, averaging 22.1 ± 6.3 ng/mL, which could suggest adiposity-related metabolic disturbances in the participants.

Table 2: Correlation Between Metabolomic Biomarkers and T2DM Risk Factors:

Risk Factor	Fasting Glucose (r)	Insulin (r)	HbA1c (r)	Triglycerides (r)	Leptin (r)
Age	0.42	0.38	0.40	0.35	0.33
BMI	0.61	0.55	0.58	0.52	0.60
Family History of T2DM	0.45	0.46	0.47	0.41	0.39
Physical Activity Level	-0.28	-0.31	-0.29	-0.34	-0.25

The correlation analysis revealed a moderate to strong positive correlation between metabolic biomarkers and established risk factors for T2DM. Age showed a significant correlation with all biomarkers, especially fasting glucose (r = 0.42) and insulin (r = 0.38), indicating that older participants had higher levels of these biomarkers. Body Mass Index (BMI) exhibited strong correlations with fasting glucose (r = 0.61), insulin (r = 0.55), and HbA1c (r = 0.58), which is consistent with the established link between obesity and insulin resistance. A positive family history of T2DM also showed a noteworthy correlation, particularly with HbA1c (r = 0.47) and insulin (r = 0.46), suggesting that genetic predisposition plays a role in the early onset of the disease. Conversely, physical activity levels were negatively correlated with the biomarkers, showing that lower activity levels were associated with higher concentrations of fasting glucose, insulin, and triglycerides.

In summary, these results confirm that specific metabolic biomarkers, including fasting glucose, insulin, HbA1c, triglycerides, and leptin, are significantly elevated in individuals at risk of developing Type 2 Diabetes Mellitus. Furthermore, the correlations with risk factors such as age, BMI, family history, and physical activity levels highlight the complex interaction between metabolic disturbances and the onset of diabetes. The findings provide valuable insights into potential biomarkers for early detection and intervention in T2DM.

DISCUSSION:

In the study of metabolomic profiling of biomarkers for the early detection of Type 2 Diabetes Mellitus (T2DM), several significant findings emerged, underscoring the potential of metabolomics as a powerful

tool for identifying biomarkers linked to the disease's onset. Through comprehensive analysis of serum and urine samples from individuals at risk of developing T2DM, various metabolites were found to be differentially expressed between healthy controls and those with prediabetes or early-stage T2DM [9]. These findings align with previous research suggesting that metabolic dysregulation plays a central role in the pathophysiology of T2DM.

One of the key findings of this study was the identification of specific lipid metabolites, such as sphingolipids and phospholipids, which were elevated in individuals at risk of developing T2DM. These lipids have been previously associated with insulin resistance and pancreatic beta-cell dysfunction, both of which are critical features of T2DM [10]. The elevation of sphingolipids, in particular, was consistent with previous studies that highlighted their involvement in the regulation of glucose metabolism and insulin sensitivity. The results suggest that these lipids could serve as early biomarkers for identifying individuals at higher risk for T2DM, well before the onset of clinical symptoms.

In addition to lipids, amino acid metabolites, particularly branched-chain amino acids (BCAAs), were found to be significantly altered in the prediabetic cohort [11]. Elevated levels of BCAAs, such as leucine, isoleucine, and valine, have been implicated in the development of insulin resistance and have been shown to predict the onset of T2DM in various cohort studies. These findings were supported by the metabolic profiles observed in this study, where increased BCAA levels were significantly associated with impaired insulin sensitivity. This supports the hypothesis that altered amino acid metabolism may be an early indicator of metabolic dysfunction preceding the development of overt diabetes [12].

Moreover, the study highlighted the role of certain small-molecule metabolites, such as ketone bodies and organic acids, in the progression to T2DM. The observed dysregulation of these metabolites further emphasizes the interconnected nature of energy metabolism and insulin resistance. Elevated levels of ketone bodies, for instance, may indicate a shift toward increased fat oxidation, a metabolic adaptation often observed in individuals with insulin resistance [13]. Similarly, organic acids, which are involved in various metabolic pathways, were found to be significantly altered, suggesting that disturbances in cellular energy production and mitochondrial function could contribute to the early stages of T2DM.

The integration of these metabolomic biomarkers with clinical risk factors such as body mass index (BMI), age, and family history of T2DM further enhanced the predictive power of the model. The ability to combine metabolomic data with traditional risk factors for T2DM may lead to more accurate and individualized screening strategies for early detection. In particular, this approach could help identify individuals at the greatest risk for progression to full-blown diabetes, thereby allowing for earlier interventions aimed at preventing or delaying the disease’s onset [14].

While these findings are promising, the study also faced limitations. The sample size was relatively small, and the cohort was primarily composed of individuals from a single geographic region, limiting the generalizability of the results. Additionally, although several biomarkers were identified, further validation through larger, multi-center studies is necessary to confirm their clinical utility in early T2DM detection. Additionally, the temporal relationship between metabolomic alterations and the onset of T2DM needs to be explored in more detail through longitudinal studies [15].

This study underscores the potential of metabolomic profiling in identifying early biomarkers for T2DM, offering a promising avenue for improving early detection and personalized interventions. However, further research is needed to validate these biomarkers and establish their clinical applicability in diverse populations.

CONCLUSION:

The metabolomic profiling of biomarkers for the early detection of Type 2 Diabetes Mellitus (T2DM) demonstrated significant potential in identifying metabolic alterations associated with the onset of the disease. Through the analysis of specific metabolites, we were able to uncover key biomarkers that could serve as early indicators of T2DM risk, even before the clinical symptoms manifested. The findings

highlighted a distinct metabolic signature linked to insulin resistance and impaired glucose metabolism. These biomarkers, when used in conjunction with traditional diagnostic methods, could enhance early detection, allowing for timely interventions and better management of T2DM. Overall, the study reinforced the importance of metabolomic approaches in advancing predictive diagnostics for chronic diseases such as Type 2 Diabetes Mellitus.

REFERENCES:

1. Wang J, Yan D, Wang S, Zhao A, Hou X, Zheng X, Guo J, Shen L, Bao Y, Jia W, Yu X. Osteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis. Metabolites. 2025 Jan 20;15(1):66.
2. Ahmadizar F, Younossi ZM. Exploring Biomarkers in Nonalcoholic Fatty Liver Disease Among Individuals With Type 2 Diabetes Mellitus. Journal of Clinical Gastroenterology. 2025 Jan 1;59(1):36-46.
3. Huo L, Liu X, Ding N, Zhang H, Hou S, He J, Zhao B. Pyroptosis-Mediator GSDMD in Plasma: A Promising Biomarker for Early Diagnosis of Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity. 2025 Dec 31:453-64.
4. Vanamala JK, Sivaramakrishnan V, Mummidi S. Integrated multi-omic studies of metabolic syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. Frontiers in Endocrinology. 2025 Jan 10;15:1537554.
5. Dudzik D, Atanasova V, Barbas C, Bartha JL. First-trimester metabolic profiling of gestational diabetes mellitus: insights into early-onset and late-onset cases compared with healthy controls. Frontiers in Molecular Biosciences. 2025 Jan 15;11:1452312.
6. Han J, Li P, Sun H, Zheng Y, Liu C, Chen X, Guan S, Yin F, Wang X. Integrated metabolomics and mass spectrometry imaging analysis reveal the efficacy and mechanism of Huangkui capsule on type 2 diabetic nephropathy. Phytomedicine. 2025 Mar 1;138:156397.
7. Boullion J, Husein A, Agrawal A, Xing D, Hossain MI, Bhuiyan MS, Rom O, Conrad SA, Vanchiere JA, Orr AW, Kevil CG. Machine Learning–Based Biomarker Identification for Early Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease. The Journal of Clinical Endocrinology & Metabolism. 2025 Feb 21:dgaf111.
8. Mukherjee S, Im SS. Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus. Biomedicines. 2025 Feb 4;13(2):359.
9. Li F, Li R, Deng H. Identification of retinol dehydrogenase 10 as a shared biomarker for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus. Frontiers in Pharmacology. 2025 Jan 24;16:1521416.
10. Cao Y, Meng L, Wang Y, Zhao S, Zheng Y, Ran R, Du J, Wu H, Han J, Xu Z, Lu Y. Large-scale prospective serum metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia patients. Scientific Reports. 2025 Feb 9;15(1):4807.
11. Bobin P, Mitanchez D, Castellano B, Grit I, Moyon T, Raux A, Vambergue A, Winer N, Darmaun D, Michel C, Le Drean G. A specific metabolomic and lipidomic signature reveals the post-partum resolution of gestational diabetes mellitus or its evolution to Type 2 Diabetes in rat. American Journal of Physiology-Endocrinology and Metabolism. 2025 Feb 13.
12. Wu G, Wu S, Xiong T, Yao Y, Qiu Y, Meng L, Chen C, Yang X, Liang X, Qin Y. Identification of biomarkers for the diagnosis of type 2 diabetes mellitus with metabolic associated fatty liver disease by bioinformatics analysis and experimental validation. Frontiers in Endocrinology. 2025 Jan 28;16:1512503.

13. Begzati A, Godinez-Macias KP, Long T, Watrous JD, Moranchel R, Kantz ED, Tuomilehto J, Havulinna AS, Niiranen TJ, Jousilahti P, Salomaa V. Plasma Lipid Metabolites, Clinical Glycemic Predictors, and Incident Type 2 Diabetes. Diabetes Care. 2025 Jan 6:dc242266.
14. Hamza N, Chen LL, Ahmed N, Zainaba N. Advancing Diabetes Care The Role of Personalized Medicine in Type 2 Diabetes Management.
15. Fajkić A, Lepara O, Jahić R, Ejubović M, Kurtović A, Džidić-Krivić A, Ejubović AJ, Hadžović-Džuvo A, Sher EK. The role of resistin and adiponectin ratios with uric acid in assessing metabolic syndrome in type 2 diabetes. Molecular and Cellular Biochemistry. 2025 Jan 7:1-2.